Clinical trials
High Risk Prostate Carcinoma clinical trials
Below are recruiting high risk prostate carcinoma clinical trials, each written for real people, not researchers. We’re tracking 124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT05488548RecruitingPhase 1
Study drug that blocks BET and CBP/p300 in advanced cancers
This Phase 1 trial tests an investigational medicine that targets BET and CBP/p300 to try to slow or control advanced, hard-to-treat cancers. You may be eligible if you have certain prostate cancer or NUT midline carcinoma, or specific blood cancers like CMML or myelofibrosis (MF), and your body functions are strong enough for chemotherapy-style treatment.
Phoenix, ArizonaAges 18 years+ - NCT07436078Recruiting
Genetic testing study for African American cancer survivors
This study offers genetic testing and counseling to African American cancer survivors. It aims to see if a culturally tailored approach helps more people understand their cancer risk and get the testing they need.
Detroit, MichiganAges 20–79 - NCT05796973RecruitingPhase 3
Exercise and atorvastatin for metastatic cancer outcomes
This trial tests whether a structured exercise program, along with the cholesterol medicine atorvastatin, can improve outcomes in people with metastatic prostate, breast, ovarian, or kidney cancer. It may help by reducing inflammation and supporting physical function during cancer treatment.
Tampere, Länsi-SuomiAges 18–99 - NCT03327675Recruiting
PET imaging test to plan personalized prostate cancer treatment
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
LeuvenAges 18 years+ - NCT06228066RecruitingPhase 2
Lurbinectedin with or without avelumab for small cell bladder cancer
This clinical trial tests a drug called lurbinectedin, given alone or with avelumab (an immunotherapy), for people with small cell bladder cancer or similar high-grade neuroendocrine tumors that have spread. The goal is to see if combining these drugs helps shrink or control the cancer better.
Bethesda, MarylandAges 18–120 - NCT04945642Recruiting
Radiation combination therapy for intermediate to high-risk prostate cancer
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
Los Angeles, CaliforniaAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07483112Recruiting
Fiber supplement study for advanced lung cancer patients
This trial tests whether adding a fiber supplement to standard immunotherapy can help treat advanced non-small cell lung cancer. It's for people whose tumors have high PD-L1 levels and no treatable genetic mutations.
BaselAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07293585RecruitingPhase 3
Precision radiation to protect erectile function in prostate cancer
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
Los Angeles, CaliforniaAges 18 years+ - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06582446RecruitingPhase 2
AI-Personalized Radiation for High-Risk Prostate Cancer
This trial tests a new way to plan prostate cancer treatment using artificial intelligence and advanced imaging. It’s for people with high-risk prostate cancer that hasn’t spread to lymph nodes or other parts of the body, and who have not had prior radiation to the prostate.
LimassolAges 18 years+ - NCT05889195Recruiting
Urine test to sort bladder cancer risk after blood in urine
This study tests whether a special urine testing approach can better identify and sort risk in people (especially veterans) who were referred to urology for blood in the urine. It may help doctors decide who needs more urgent follow-up and which next steps to take.
Murrieta, CaliforniaAges 18–89 - NCT07182279RecruitingPhase 1/Phase 2
Internal radiation before prostate surgery for high-risk cancer
This trial tests a treatment approach for newly diagnosed, high-risk prostate cancer. You would receive a short course of internal radiation (high-dose-rate brachytherapy) before surgery to remove your prostate. The goal is to see if this combination is safe and works better than surgery alone.
Houston, TexasAges 40 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Kingman, ArizonaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06445114RecruitingPhase 2
Blood-Guided Chemoradiation for HPV-Positive Throat Cancer
This study tests whether a blood test that looks for circulating HPV DNA (ctDNA) can help doctors decide if you need chemotherapy after surgery for HPV-positive throat cancer. After you have surgery to remove the cancer, you receive radiation (possibly with chemotherapy) — the results of the blood test guide whether or not to add chemo.
Beverly Hills, CaliforniaAges 18 years+
Hear when a new High Risk Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk prostate carcinoma?
- Yes. Clin2 currently lists 124 recruiting high risk prostate carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk prostate carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk prostate carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.